How much, and by what mechanisms, does growth hormone replacement improve the quality of life in GH-deficient adults?

被引:18
|
作者
Chrisoulidou, A [1 ]
Kousta, E [1 ]
Beshyah, SA [1 ]
Robinson, S [1 ]
Johnston, DG [1 ]
机构
[1] St Marys Hosp, Imperial Coll, Sch Med, Div Med,Sect Endocrinol & Metab Med, London W2 1NY, England
来源
关键词
quality of life; growth hormone deficiency; adults;
D O I
10.1016/S0950-351X(98)80022-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The majority of studies (but not all) have demonstrated that adults with hypopituitarism of both childhood and adult onset have a diminished quality of life (QOL) in comparison with the normal population. Reductions in physical and mental energy, dissatisfaction with body image and poor memory have been reported most consistently. A specific role for growth hormone (GPI) deficiency, as opposed to multiple pituitary hormone deficiency, has been observed for the memory deficit, which extends to both short- and long-term memory. Comparisons with normal siblings have confirmed the reduced QOL, although differences have been small. There is less consensus far a reduction in QOL when hypopituitary subjects are compared with patients with other chronic diseases, with studies supporting tin comparison with diabetics) and refuting tin comparison with patients following mastoid surgery) the reduction in QOL. GH replacement in adults has improved QOL, particularly in the domains of energy level and self-esteem: and memory has improved. The social impact of these changes may be considerable, with patients requiring fewer days' sick leave. A major placebo effect is present, however, and neutral results as well as positive have been reported in placebo-controlled trials. Where a positive effect has been observed, it has been more likely to occur in patients with a low QOL at the outset. It is otherwise impossible to predict at the outset those who will benefit from GH replacement. GH treatment has effects on body composition, exercise capacity, muscle strength, total body water and intermediary metabolism which would be expected to improve QOL. Replacement therapy also has side-effects, and it is the variable balance of the positive and negative effects, coupled with the difficulties of measuring QOL, which have led to the disparate results in the literature. There is probably also a true interindividual variation, although the mechanisms of this are currently unknown.
引用
收藏
页码:261 / 279
页数:19
相关论文
共 50 条
  • [1] Growth hormone replacement does not elevate albuminuria in GH-deficient adults
    Oomen, PHN
    Beentjes, JAM
    Dullaart, RPF
    [J]. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2002, 62 (01): : 1 - 6
  • [2] An audit of growth hormone replacement for GH-deficient adults in Scotland
    Philip, Sam
    Howat, Isobel
    Carson, Maggie
    Booth, Anne
    Campbell, Karen
    Grant, Donna
    Patterson, Catherine
    Schofield, Christopher
    Bevan, John
    Patrick, Alan
    Leese, Graham
    Connell, John
    [J]. CLINICAL ENDOCRINOLOGY, 2013, 78 (04) : 571 - 576
  • [3] Ten Years of Growth Hormone (GH) Replacement Normalizes Muscle Strength in GH-Deficient Adults
    Gotherstrom, Galina
    Elbornsson, Mariam
    Stibrant-Sunnerhagen, Katharina
    Bengtsson, Bengt-Ake
    Johannsson, Gudmundur
    Svensson, Johan
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (03): : 809 - 816
  • [4] Growth hormone and serum leptin in GH-deficient adults
    Bianda, T
    Froesch, ER
    Schmid, C
    [J]. CLINICAL ENDOCRINOLOGY, 1997, 47 (04) : 502 - 502
  • [5] Does growth hormone (GH) enhance growth in GH-deficient children with myelomeningocele?
    Trollmann, R
    Strehl, E
    Wenzel, D
    Dörr, HG
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08): : 2740 - 2743
  • [6] Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults
    Cook, DM
    Ludlam, WH
    Cook, MB
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11): : 3956 - 3960
  • [7] The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults
    Bengtsson, BÅ
    Abs, R
    Bennmarker, H
    Monson, JP
    Feldt-Rasmussen, U
    Hernberg-Ståhl, E
    Westberg, B
    Wilton, P
    Wüster, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11): : 3929 - 3935
  • [8] The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults
    Gilchrist, FJ
    Murray, RD
    Shalet, SM
    [J]. CLINICAL ENDOCRINOLOGY, 2002, 57 (03) : 363 - 370
  • [9] Growth hormone (GH) replacement therapy in GH-deficient women during pregnancy
    Wirén, L
    Boguszewski, CL
    Johannsson, G
    [J]. CLINICAL ENDOCRINOLOGY, 2002, 57 (02) : 235 - 239
  • [10] Growth hormone therapy in GH-deficient adults: The problem of the dose
    Amato, G
    Bellastella, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (04): : 1304 - 1305